Literature DB >> 29351984

Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.

Nelson Leung1,2, Stephan D Thomé3, Angela Dispenzieri4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29351984      PMCID： PMC5830371          DOI： 10.3324/haematol.2017.183749

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Molecular mechanisms of amyloidosis.

Authors:  Giampaolo Merlini; Vittorio Bellotti
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

2.  Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).

Authors:  Cyrille Touzeau; Steven Le Gouill; Béatrice Mahé; Jean Samuel Boudreault; Thomas Gastinne; Nicolas Blin; Hélène Caillon; Christelle Dousset; Martine Amiot; Philippe Moreau
Journal:  Haematologica       Date:  2017-01-05       Impact factor: 9.941

3.  A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.

Authors:  Giovanni Palladini; Sajitha Sachchithanantham; Paolo Milani; Julian Gillmore; Andrea Foli; Helen Lachmann; Marco Basset; Philip Hawkins; Giampaolo Merlini; Ashutosh D Wechalekar
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

4.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

5.  Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

Authors:  Alan H Bryce; Rhett P Ketterling; Morie A Gertz; Martha Lacy; Ryan A Knudson; Steven Zeldenrust; Shaji Kumar; Suzanne Hayman; Francis Buadi; Robert A Kyle; Philip R Greipp; John A Lust; Stephen Russell; S Vincent Rajkumar; Rafael Fonseca; Angela Dispenzieri
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

Review 6.  Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.

Authors:  Nelson Leung; Frank Bridoux; Colin A Hutchison; Samih H Nasr; Paul Cockwell; Jean-Paul Fermand; Angela Dispenzieri; Kevin W Song; Robert A Kyle
Journal:  Blood       Date:  2012-10-09       Impact factor: 22.113

7.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

8.  Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.

Authors:  Tilmann Bochtler; Ute Hegenbart; Friedrich W Cremer; Christiane Heiss; Axel Benner; Dirk Hose; Marion Moos; Jelena Bila; Claus R Bartram; Anthony D Ho; Hartmut Goldschmidt; Anna Jauch; Stefan O Schonland
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

Review 9.  Development of venetoclax for therapy of lymphoid malignancies.

Authors:  Huayuan Zhu; Alexandru Almasan
Journal:  Drug Des Devel Ther       Date:  2017-03-09       Impact factor: 4.162

10.  The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.

Authors:  C Touzeau; C Dousset; S Le Gouill; D Sampath; J D Leverson; A J Souers; S Maïga; M C Béné; P Moreau; C Pellat-Deceunynck; M Amiot
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528
  10 in total
  15 in total

Review 1.  Novel Approaches for the Management of AL Amyloidosis.

Authors:  Nisha S Joseph; Jonathan L Kaufman
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 2.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

Review 3.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Blood Cancer J       Date:  2021-05-15       Impact factor: 11.037

Review 4.  Comprehensive Review of AL amyloidosis: some practical recommendations.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Ali Bazarbachi; Florent Malard; Jean-Luc Harousseau; Mohamad Mohty
Journal:  Blood Cancer J       Date:  2021-05-18       Impact factor: 11.037

Review 5.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.

Authors:  Morie A Gertz
Journal:  Blood Cancer J       Date:  2018-05-23       Impact factor: 11.037

6.  Light chain lambda myeloma with fatal AL cardiac amyloidosis in a 21-year-old patient: A case report and review.

Authors:  Vincent Camus; Sydney Dubois; Pierre-Alain Thiébaut; Stéphane Lepretre; Pascal Lenain; Jean-Michel Picquenot; Elena-Liana Veresezan; Arnaud François; Dominique Penther; Fabrice Bauer; Arnaud Jaccard; Fabrice Jardin
Journal:  Clin Case Rep       Date:  2019-05-07

7.  Approach to a patient with cardiac amyloidosis.

Authors:  Christopher Strouse; Alexandros Briasoulis; Rafael Fonseca; Yogesh Jethava
Journal:  J Geriatr Cardiol       Date:  2019-07       Impact factor: 3.327

Review 8.  Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.

Authors:  Shayna Sarosiek; Vaishali Sanchorawala
Journal:  J Blood Med       Date:  2019-10-23

Review 9.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20

10.  Cardiac amyloidosis presenting with recurrent ischaemic strokes.

Authors:  Suleiman Suleiman; John Joseph Coughlan; David Moore
Journal:  BMJ Case Rep       Date:  2020-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.